Arnab Ray

Advances in the diagnosis and treatment of Clostridium difficile infections

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection

Microbiota in health and diseases

Non-traditional Antibacterial Therapeutic Options and Challenges

Synthesis of stress proteins in rat cardiac myocytes 2-4 days after imposition of hemodynamic overload.

Antibiotic resistance: a rundown of a global crisis

Hallmarks of aging: An expanding universe

Systematic Review: Adverse Events of Fecal Microbiota Transplantation

Antibiotic development — economic, regulatory and societal challenges

Emerging Trends in “Smart Probiotics”: Functional Consideration for the Development of Novel Health and Industrial Applications

Changes in Gene Expression during Cardiac Growth

Current Evidence in Delivery and Therapeutic Uses of Fecal Microbiota Transplantation in Human Diseases—Clostridium difficile Disease and Beyond

NF-κB, inflammation, immunity and cancer: coming of age

Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

The pros, cons, and many unknowns of probiotics

The gut microbiome as a modulator of healthy ageing

Fibrosis, not cell size, delineates β-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection

Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

Molecular Mechanisms of Myocardial Remodeling

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

Safety and Durability of RBX2660 (Microbiota Suspension) for RecurrentClostridium difficileInfection: Results of the PUNCH CD Study

The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals

Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection

Protein and 28S ribosomal RNA fractional turnover rates in the rat heart after abdominal aortic stenosis

Fecal Microbiota Transplantation for Clostridium difficile Infection: The Ochsner Experience.

Does the Donor Matter? Donor vs Patient Effects in the Outcome of a Next-Generation Microbiota-Based Drug Trial for Recurrent Clostridium Difficile Infection